A Two-arm, Phase 1b/2 Study of Duvelisib Administered in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma

Trial Profile

A Two-arm, Phase 1b/2 Study of Duvelisib Administered in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Duvelisib (Primary) ; Obinutuzumab; Rituximab
  • Indications Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CONTEMPO
  • Sponsors Infinity Pharmaceuticals; Verastem
  • Most Recent Events

    • 24 May 2017 This trial has been completed in Spain.
    • 21 Feb 2017 Planned End Date changed from 1 Jan 2020 to 1 Apr 2017.
    • 06 Dec 2016 Preliminary results (n=55, data cut off 19 Jul 2016) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top